RecruitingNCT05799118
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Sponsor
Cyprus Institute of Neurology and Genetics
Enrollment
30,000 participants
Start Date
Oct 1, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Eligibility
Min Age: 2 Years
Inclusion Criteria3
- Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered.
- Age ≥ 2 years old at the time of the collection of the phenotypic data.
- There will be no limits on study participants in terms of gender, ethnicity, morbidities.
Exclusion Criteria3
- Patients treated with stem cell transplantation or genetic therapy.
- Age < 2 years old at the time of the collection of the phenotypic data.
- Patient or legal representative for minors unwilling or unable to give consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
GENETICGWAS
The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05799118
Related Trials
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
NCT039378171 location
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT0697586554 locations
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT0643908231 locations
Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders
NCT044161781 location
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
NCT032143541 location